文献速递青光眼

良性前列腺增生使用α受体阻滞剂与急性闭角型青光眼的关联

Association Between Alpha-Blockers for Benign Prostatic Hyperplasia and Acute Angle-Closure Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2025-11-13

该回顾性临床队列研究基于韩国国民健康保险共享服务2002至2022年全国健康记录,纳入30450名参与者(5075例急性闭角型青光眼病例与25375名匹配对照),发现良性前列腺增生患者使用α受体阻滞剂与急性闭角型青光眼风险显著增加相关(调整后HR 1.52;95%CI 1.40-1.66;P<.001),且呈剂量-反应关系。

要点

  • 良性前列腺增生患者使用α受体阻滞剂与急性闭角型青光眼风险显著增加相关(调整后HR 1.52;95%CI 1.40-1.66;P<.001)。
  • 急性闭角型青光眼发生率随累积用药时长增加而升高:≤23天组0.15%,≥203天组0.41%。
  • 作者认为开具α受体阻滞剂时进行眼科评估可能有价值,尤其对解剖上易发生闭角事件的患者。

核心结论

  • 该研究显示良性前列腺增生使用α受体阻滞剂与急性闭角型青光眼风险增加存在显著的时长依赖性关联。
  • 作者认为这些发现强调开具α受体阻滞剂时进行眼科评估的潜在价值,尤其对解剖上易发生闭角事件的患者。

研究设计与样本

  • 回顾性临床队列研究,分析韩国国民健康保险共享服务2002至2022年全国健康记录。
  • 采用基线协变量创建1:5倾向评分匹配队列,最终纳入30450名参与者,包括5075例急性闭角型青光眼病例和25375名匹配对照。
  • α受体阻滞剂用于良性前列腺增生的识别需同时存在良性前列腺增生诊断(KCD编码N40)和急性闭角型青光眼诊断前的相应处方。
  • 按累积用药时长分为三组:第1类(≤23天)、第2类(24-202天)、第3类(≥203天)。
  • 急性闭角型青光眼病例通过诊断和操作编码识别,使用Cox比例风险模型估计风险比(HR)。

主要发现

  • 与未使用相比,使用α受体阻滞剂与急性闭角型青光眼风险显著增加相关(调整后HR 1.52;95%CI 1.40-1.66;P<.001)。
  • 观察到剂量-反应关系,急性闭角型青光眼发生率从暴露≤23天使用者的0.15%增加至≥203天使用者的0.41%。

关键数值与推荐

  • 良性前列腺增生诊断采用KCD编码N40。
  • 累积用药时长分组:第1类≤23天,第2类24-202天,第3类≥203天。

临床怎么用

  • 作者认为开具α受体阻滞剂时进行眼科评估可能有价值,尤其对解剖上易发生闭角事件的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between alpha (α)-blockers use for benign prostatic hyperplasia (BPH) and the incidence of acute angle-closure glaucoma (AACG) in a nationwide population-based cohort. DESIGN: Retrospective clinical cohort study. PARTICIPANTS: This study analyzed data from the Korean National Health Insurance Sharing Service, encompassing nationwide health records from 2002 to 2022. A 1:5 propensity score-matched cohort was created using baseline covariates, ensuring balance between AACG cases and matched controls. METHODS: Alpha-blocker use for BPH was identified by the presence of both a BPH diagnosis (KCD code N40) and a corresponding prescription prior to AACG diagnosis. Patients were categorized into three groups based on cumulative medication duration: Category 1 (≤23 days), Category 2 (24-202 days), and Category 3 (≥203 days). MAIN OUTCOMES AND MEASURES: Incident AACG cases were identified using diagnostic and procedure codes, and hazard ratios (HR) were estimated using Cox proportional hazards models. RESULTS: The final cohort included 30 450 participants, comprising 5075 AACG cases and 25 375 matched controls. Alpha-blocker use was associated with a significantly increased risk of AACG (adjusted HR, 1.52; 95% CI, 1.40-1.66; P < .001) compared to nonuse. A dose-response relationship was observed, with AACG incidence increasing from 0.15% among users with ≤23 days of exposure to 0.41% among those with ≥203 days. CONCLUSIONS: This study demonstrates a significant, duration-dependent association between α-blocker use for BPH and an increased risk of AACG. These findings underscore the potential value of ophthalmologic evaluation when prescribing α-blockers, particularly for patients who may be anatomically predisposed to angle-closure events.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Baek SU, Kim SH, Ha A, et al. Association Between Alpha-Blockers for Benign Prostatic Hyperplasia and Acute Angle-Closure Glaucoma. Am J Ophthalmol. 2025. PMID: 41241361. doi:10.1016/j.ajo.2025.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。